Trade Summary

Yesterday, Callos Andrew, serving as EVP, Chief Commercial Officer at Cytokinetics Inc (CYTK), sold 1,798 shares at $62.62 per share, for a total transaction value of $112,585.00. Following this transaction, Callos Andrew now holds 50,440 shares of CYTK.

This sale represents a 3.00% decrease in Callos Andrew's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, January 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, January 2, 2026, meaning the disclosure happened on the same day as the trade.

Cytokinetics Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.